The Ratings Game: AbbVie’s new, cheaper hepatitis C drug could launch the drug world’s own Hunger Games

AbbVie Inc.’s newly approved drug Mavyret can treat hepatitis C’s six major strains in eight weeks.

It’s also a positive steal in the hepatitis C drug world, at $26,400 for a eight-week course of treatment.

That’s on paper, at least, according to a chart from EvercoreISI analyst Umer Raffat, which shows AbbVie’s ABBV, +0.00% Mavyret coming in cheaper than the company’s other hepatitis C therapies, Viekira Pak and Viekira XR, Gilead Sciences Inc.’s GILD, -1.63% Sovaldi, Harvoni, Epclusa and Vosevi, and Merck’s MRK, -0.66% Zepatier.

Gilead shares declined 2.2% in heavy midday trade on Friday, and Merck shares slumped 0.7% in light-to-moderate trade.

>>> Original Source <<<